[ad_1] Looking forward to presenting at @Eyecelerator during this week’s annual meeting of the @aao_ophth! Now, #clinicaltrials involving suprachoroidal delivery include a tyrosine kinase inhibitor, a corticosteroid, a #genetherapy & a virus-like drug conjugate https://t.co/qgyOQb2YzJ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …

[ad_1] RT @eyetubenet: Are you attending the #AAO2022 Annual Meeting?! Join us in-person or virtually for a #CME Symposium. ‘Into the Suprachoroi… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Our paper, https://t.co/vztXKnKI4P “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO-Related M… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @JCRnEDITORS: Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions. | Thomas A. Ciulla @… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Recent article @RetinalPhys: #Suprachoroidal Drug Delivery Technology. After #Xipere’s approval, SC #drugdelivery is clinical reality. 4 therapies delivered SC are in #clinicaltrials: a corticosteroid, a TKI, a #genetherapy & a virus-like drug conjugate. https://t.co/iIkyKHNh4r [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …

[ad_1] RT @ThomasCiullaMD: Just published, “Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions”… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Our paper, https://t.co/vztXKnKI4P “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO-Related Macular Edema” now appears in print, in this month’s Ophthalmology Retina. More effective & durable therapies are needed. #eyes #retina #diabetes https://t.co/aOsmK3A9fx [ad_2] Source by Thomas Ciulla, MD, MBA Return to …